Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab consolidation in stage III NSCLC
NCT03884192Phase 3Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03884192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884192.